Sun Yat-sen University: Breast Neoplasms trials

The registry lists 56 Breast Neoplasms studies with Sun Yat-sen University as lead sponsor. 23 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 27Phase 3 14No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingNCT07732491Phase 2
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2
• Megestrol Acetate for Fatigue Management in T-DXd Treated Breast CancerRecruitingNCT07543536Phase 3
• A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug ConjugatesRecruitingNCT07520760Phase 2
• FMD and Neoadjuvant Chemo-immunotherapy in TNBCRecruitingNCT07378306Phase 2
• Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 InhibitorsRecruitingNCT07258108Phase 2
• Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingNCT07255612Phase 2
• A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07235618Phase 2
• Adaptive Chemotherapy for the Treatment of Advanced Breast CancerRecruitingNCT07088263Phase 3
• Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal ComponentNot yet recruitingNCT07060599Not applicable
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast CancerRecruitingNCT06900647Phase 1
• Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast CancerRecruitingNCT06877416
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast CancerRecruitingNCT06768931Phase 2
• Arsenous Acid for Refractory Triple-Negative Breast CancerRecruitingNCT06678048Phase 2
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsRecruitingNCT06551220
• Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast CancerNot yet recruitingNCT06383663Not applicable
• Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast CancerRecruitingNCT06268652Phase 3
• Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)RecruitingNCT06195202
• Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT05430399Phase 3
• Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT05172518Phase 3
• Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast CancerRecruitingNCT04941885Phase 2
• Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR MutationRecruitingNCT04936295Phase 2
• A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTientsRecruitingNCT03561740Phase 3
• Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast CancerCompletedNCT03045653Phase 2Results posted
• Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer PatientsCompletedNCT07052734
• Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)Active, not recruitingNCT06618014Phase 2
• Adaptive Therapy for Post-Second-Line Advanced Breast CancerCompletedNCT06533722Phase 2
• Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer PatientsCompletedNCT06373744
• Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure)Status unknownNCT05773391Not applicable
• Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.Status unknownNCT05749575Phase 2
• GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast CancerTerminatedNCT05239663Phase 3
• Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast CancerCompletedNCT05114720Phase 3
• Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast CancerStatus unknownNCT04605575Phase 2
• GM1 Prophylaxis for WBRT Related Cognitive DysfunctionTerminatedNCT04395339Phase 3
• Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
• Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and PertuzumabStatus unknownNCT04255056Phase 2
• Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water ImmersionStatus unknownNCT04215744Not applicable
• ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingNCT04172259Phase 2
• A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerStatus unknownNCT03997539Phase 2
• Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast CancerStatus unknownNCT03993964Phase 2
• Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast CancerTerminatedNCT03702868
• A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer PatientsStatus unknownNCT03543072
• A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer PatientsStatus unknownNCT03543059
• Routine Therapy Plus Moxifloxacin in Advanced Breast CancerCompletedNCT03405168Phase 2
• Evaluation of Epalrestat in Metastatic Triple-negative Breast CancerTerminatedNCT03244358Phase 2
• Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast CancerTerminatedNCT03055312Phase 3
• Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerCompletedNCT02767661Phase 3
• Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast CancerCompletedNCT02468739Phase 3
• A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast CancerCompletedNCT02362958Phase 2
• Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyTerminatedNCT02362230Phase 2
• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerTerminatedNCT02183805Phase 2
• Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerStatus unknownNCT02000193Phase 2
• Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast CancerCompletedNCT01950182Phase 3
• Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing StrategyStatus unknownNCT01891123Not applicable
• A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT01462903Phase 1
• Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast CancerCompletedNCT01112826Phase 3